These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Basic principles in thrombolysis: regulatory role of plasminogen. Rijken DC; Sakharov DV Thromb Res; 2001 Sep; 103 Suppl 1():S41-9. PubMed ID: 11567668 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody. Hendrickx ML; Zatloukalova M; Hassanzadeh-Ghassabeh G; Muyldermans S; Gils A; Declerck PJ Thromb Haemost; 2014 May; 111(5):824-32. PubMed ID: 24402608 [TBL] [Abstract][Full Text] [Related]
11. Antifibrinolytic mechanisms in acute airway injury after sulfur mustard analog inhalation. Rancourt RC; Ahmad A; Veress LA; Rioux JS; Garlick RB; White CW Am J Respir Cell Mol Biol; 2014 Oct; 51(4):559-67. PubMed ID: 24796565 [TBL] [Abstract][Full Text] [Related]
12. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944 [TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism. Orbe J; Barrenetxe J; Rodriguez JA; Vivien D; Orset C; Parks WC; Birkland TP; Serrano R; Purroy A; Martinez de Lizarrondo S; Angles-Cano E; Páramo JA Circulation; 2011 Dec; 124(25):2909-19. PubMed ID: 22104553 [TBL] [Abstract][Full Text] [Related]
14. Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models. Leenaerts D; Loyau S; Mertens JC; Boisseau W; Michel JB; Lambeir AM; Jandrot-Perrus M; Hendriks D J Thromb Haemost; 2018 Oct; 16(10):2057-2069. PubMed ID: 30053349 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model. Vercauteren E; Emmerechts J; Peeters M; Hoylaerts MF; Declerck PJ; Gils A Blood; 2011 Apr; 117(17):4615-22. PubMed ID: 21343611 [TBL] [Abstract][Full Text] [Related]
16. Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody. Develter J; Booth NA; Declerck PJ; Gils A J Thromb Haemost; 2008 Nov; 6(11):1884-91. PubMed ID: 18752580 [TBL] [Abstract][Full Text] [Related]
17. A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects. Zhou J; Kochan J; Yin O; Warren V; Zamora C; Atiee G; Pav J; Orihashi Y; Vashi V; Dishy V J Thromb Haemost; 2017 May; 15(5):961-971. PubMed ID: 28211169 [TBL] [Abstract][Full Text] [Related]
18. Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa). Schaffner AP; Sansilvestri-Morel P; Despaux N; Ruano E; Persigand T; Rupin A; Mennecier P; Vallez MO; Raimbaud E; Desos P; Gloanec P J Med Chem; 2021 Apr; 64(7):3897-3910. PubMed ID: 33764059 [TBL] [Abstract][Full Text] [Related]
19. The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood. Carrieri C; Galasso R; Semeraro F; Ammollo CT; Semeraro N; Colucci M J Thromb Haemost; 2011 Jan; 9(1):154-62. PubMed ID: 20961395 [TBL] [Abstract][Full Text] [Related]